A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
NCT04135495
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class
Conditions
Cystic Fibrosis
Interventions
DRUG:
ELX-02
DRUG:
Ivacaftor
Sponsor
Eloxx Pharmaceuticals, Inc.